Rithin Nedumannil

12PUBLICATIONS
29CO-AUTHORS
HaematologyCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyInstruments and techniquesHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Dec 18, 2025
Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia.

Alice J Liu, Emily Batterham, Rithin Nedumannil

|Jul 29, 2025
Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML.

Rithin Nedumannil, Michael Ashby, James Rowland

|Feb 10, 2025
Serial sensitive molecular detection of JAK2 V617F is predictive of relapse after allogeneic stem cell transplantation in patients with myelofibrosis.

Rithin Nedumannil, Tal Karmi, Piers Blombery

|Jan 10, 2024
Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemia.

Zoe Loh, Michael Ashby, Ellie Van Veldhuizen

|Sep 01, 2023
Consecutive day dosing of high-dose cytarabine consolidation over 3 days is resource-efficient and safe in older adult patients with acute myeloid leukemia.

Rithin Nedumannil, Emily Batterham, Emily Harding

|Nov 02, 2022
Real-world utility of early measurable residual disease assessments by multi-parametric flow cytometry in adult patients with B-lymphoblastic leukemia receiving Hyper-CVAD induction chemotherapy.

Rithin Nedumannil, David Ritchie, Ashish Bajel

Pageof 2

Frequent Collaborators

3 joint publications

Ashish Bajel

2 joint publications

Piers Blombery

2 joint publications

Andrew H Wei

2 joint publications

David S Ritchie